Results 171 to 180 of about 35,844 (248)

Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis. [PDF]

Front Oncol
Xu Y, Lai J, Mai M, Tang Y, Wu Z.
europepmc   +1 more source

Excellent Results in the Off-Label Use of Denosumab in Pediatric Oncology: Monocentric Case Series Study. [PDF]

Case Rep Pediatr
Battaglia T, Nebiolo M, Conte M, Livellara V, Piatelli G, Damasio MB, Galleni B, Arkhangelskaya E, Manzitti C, Gaggero G, Garaventa A.   +10 more
europepmc   +1 more source

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events [PDF]

, 2015

openalex   +1 more source

Denosumab as a treatment for pediatric hypercalcemia-a multicenter experience. [PDF]

JBMR Plus
Hobbs A, Nair R, Ludwig K, Ambler GR, Munns CF.   +4 more
europepmc   +1 more source

SEOM Clinical Guideline for bone metastases from solid tumours (2016) [PDF]

, 2016

core   +1 more source

Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis. [PDF]

Front Oncol
Zhong L, Chen W, Zheng D, Cao Y, Zhu L, Zhu Z, Liao L, Dai L, Wang X, Zeng Z.   +9 more
europepmc   +1 more source

Effectiveness and safety of romosozumab followed by 2 years of sequential therapy with denosumab in a real-world setting

Kazuaki Mineta, Toshihiko Nishisho, Masahiko Okada, Mitsuhiro Kamada, Koichi Sairyo   +4 more
openalex   +1 more source

Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force. [PDF]

Endocrinol Metab (Seoul)
Kim JW, Kong SH, Kim JY, Kwak MK, Kim JY, Oh JH, Park HY, Kim B, Lee YK, Han JJ, Kim MY, Choi YJ, Kwon YD, Song KS, Kim BJ, Kim SJ, Baek SH, Lee DO, Choi HS, Kim HY, Kwon TG.   +20 more
europepmc   +2 more sources

Denosumab treatment of osteoporotic women arrests cortical bone remodeling events at the reversal-resorption phase but does not affect ongoing bone formation. [PDF]

JBMR Plus
Dahl XG, Roux JP, Delaisse JM, Huang S, Chavassieux P, Andreasen CM, Andersen TL.   +6 more
europepmc   +1 more source

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)

Lingyan Kong, Jun Ma
openalex   +1 more source